Phase
Condition
Stimulant Use Disorder
Treatment
TAU
SUVO
Clinical Study ID
Ages 18-65 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Meet Diagnostic and Statistical Manual of Mental Disorders(DSM-5)criteria forprimary stimulant use disorder (either cocaine or methamphetamine)
Be fluent in English and able to understand the consent form
Exclusion
Exclusion Criteria:
Have an opioid use disorder of any severity
Have a greater than moderate substance use disorder on any other substance
Undergoing medication-assisted treatment for withdrawal of any substance
Have any medical conditions contraindicating SUVO (e.g., severe pulmonary disease,severe cardiovascular disease or clinically abnormal ECG, severe liver or kidneydisease, seizure disorder, or sleep disorder -particularly narcolepsy)
Are currently taking medications with known drug interactions with SUVO (e.g.,Monoamine oxidase (MAO) inhibitors, anticonvulsants, haloperidol, phenothiazines,anesthetics, and any sedative)
Are pregnant or breast feeding
BMI > 30 (women only)
Have a current DSM-5 psychiatric disorder or neurological disease requiring on-goingtreatment that would make participation unsafe
Have history of seizure disorder
Have a head injury with loss of consciousness in the last 5 years
Study Design
Connect with a study center
The University of Texas Health Science Center at Houston
Houston, Texas 77030
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.